Abstract
Previous studies have indicated that carcinoembryonic antigen (CEA) and cancer antigen 15–3 (CA15-3) levels are both independent prognostic factors in breast cancer. However, the utility of CEA and CA15-3 levels as conventional cancer biomarkers in patients with triple-negative breast cancer (TNBC) remains controversial. The current study was performed to explore the predictive value of pre-therapeutic serum CEA and CA15-3 levels, and nomograms were developed including these serum cancer biomarkers to improve the prognostic evaluation of TNBC patients. Pre-therapeutic CA15-3 and CEA concentrations were measured in 247 patients with stage I–IV TNBC. Kaplan-Meier analysis showed that TNBC patients with high levels of both CEA and CA15-3 had shorter overall survival (OS) and disease-free survival (DFS) rates than those in the low-level groups (p<0.05). Multivariate analysis suggested that pre-therapeutic CA15-3 and CEA levels are independent predictive elements for OS (p = 0.022 and p = 0.040, respectively) and DFS (p = 0.023 and p = 0.028, respectively). In addition, novel nomograms were established and validated to provide personal forecasts of OS and DFS for patients with TNBC. These novel nomograms may help physicians to select the optimal treatment plans to ensure the best outcomes for TNBC patients.
Highlights
Triple-negative breast cancer (TNBC) is a hypotype of breast cancer that is immunohistochemically based on the negative expression of the hormone receptors estrogen receptor (ER) and progesterone receptor (PR) and on the negative amplification of HER2 amplification[1]
Clinical analysis was performed for 247 female patients, and all of them were definitively diagnosed with triple-negative breast cancer and were treated with modified radical mastectomy at the Sun Yat-sen University Cancer Center (SYSUCC) in Guangzhou, China, between January 2004 and December 2009
The mean value of the pre-therapeutic carcinoembryonic antigen (CEA) level was 8.83± 54.67 ng/ml, and it was correlated with tumor status, N status, and TNM staging
Summary
Triple-negative breast cancer (TNBC) is a hypotype of breast cancer that is immunohistochemically based on the negative expression of the hormone receptors estrogen receptor (ER) and progesterone receptor (PR) and on the negative amplification of HER2 amplification[1]. The incidence of TNBC only accounts for a small proportion (10–17%) of all breast. Prognostic Value of CA15-3 and CEA in TNBC role in study design, data collection and analysis, decision to publish, or preparation of the manuscript
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
